Keywords
Last Name

Vaishali Sanchorawala, MBBS

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionHematology & Medical Oncology
Address732 Harrison Ave
Boston MA 02118
Phone(617) 638-7017
ORCID ORCID Icon0000-0002-6307-2445
Other Positions
TitleDirector
InstitutionBoston University School of Medicine
DepartmentAmyloidosis Center

TitleActive Staff Hospital Privileges
InstitutionBoston Medical Center
DepartmentMedicine

 Research Expertise & Professional Interests
Expertise includes: AL amyloidosis - clinical trials, treatment; Stem cell transplantation; Myeloma.

 Self-Described Keywords
  • Amyloidosis [C18.452.845.500]
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2016 Dec 12. PMID: 27965280.
    View in: PubMed
  2. Uwumugambi NA, Sanchorawala V, Shelton AC, Stern L, Gordon CE. Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis. Am J Kidney Dis. 2017 Feb; 69(2):317-319. PMID: 27780577.
    View in: PubMed
  3. Prokaeva T, Spencer B, Sun F, O'Hara RM, Seldin DC, Connors LH, Sanchorawala V. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid. 2016 Dec; 23(4):214-220. PMID: 27677679.
    View in: PubMed
  4. Shu J, Lo S, Phillips M, Sun F, Seldin DC, Berenbaum I, Berk JL, Sanchorawala V. Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients. Amyloid. 2016 Sep; 23(3):188-193. PMID: 27460276.
    View in: PubMed
  5. Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016 Oct; 30(10):1979-1986. PMID: 27416985.
    View in: PubMed
  6. Havasi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016 Oct; 91(10):E458-60. PMID: 27356490.
    View in: PubMed
  7. Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016 Aug 25; 128(8):1059-62. PMID: 27381904.
    View in: PubMed
  8. Dittus C, Uwumugambi N, Sun F, Sloan JM, Sanchorawala V. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Sep; 22(9):1729-32. PMID: 27296954.
    View in: PubMed
  9. Arun M, Sloan SB, Shelton A, Sanchorawala V. Penile ulcers complicating systemic AL amyloidosis: a case report. Amyloid. 2016 Sep; 23(3):203-204. PMID: 27187183.
    View in: PubMed
  10. Lee SY, Meehan RS, Seldin DC, Sloan JM, Quillen K, Shelton A, Brauneis D, Sanchorawala V. Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplant. 2016 Oct; 51(10):1318-1322. PMID: 27183092.
    View in: PubMed
  11. Sanchorawala V, Gale RP. David C Seldin, MD, PhD: scientist, clinician, teacher, gentleman, 1957-2015. Bone Marrow Transplant. 2016 Mar; 51(3):323. PMID: 26931484.
    View in: PubMed
  12. Sissoko M, Sanchorawala V, Seldin D, Sworder B, Angelino K, Broce M, Berk J, Sloan JM. Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid. 2015; 22(4):229-35. PMID: 26488936.
    View in: PubMed
  13. Bever KM, Masha LI, Sun F, Stern L, Havasi A, Berk JL, Sanchorawala V, Seldin DC, Sloan JM. Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica. 2016 Jan; 101(1):86-90. PMID: 26452981.
    View in: PubMed
  14. Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015 Nov 12; 126(20):2345-7. PMID: 26443620.
    View in: PubMed
  15. Bosch N, Renteria AS, Quillen K, Brauneis D, Santilli J, Kim D, Sanchorawala V. Nonoperative Management of Spontaneous Splenic Rupture in a Patient with Light-Chain Amyloidosis: A Case Report. J Vasc Interv Radiol. 2015 Oct; 26(10):1578-80. PMID: 26408221.
    View in: PubMed
  16. Lee SY, Brauneis D, Stern L, Sanchorawala V. Optimal dosing of high-dose melphalan prior to autologous hematopoietic stem cell transplantation in a patient with AL amyloidosis and a solitary kidney. Hematol Oncol Stem Cell Ther. 2016 Jun; 9(2):86-8. PMID: 26303745.
    View in: PubMed
  17. Skinner M, Sanchorawala V. In memoriam David C. Seldin, MD, PhD. Amyloid. 2015; 22(3):145-6. PMID: 26300106.
    View in: PubMed
  18. Sarosiek S, Seldin DC, Connors LH, Spencer B, Murakami A, O'Hara C, Sanchorawala V. Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of literature. Amyloid. 2015; 22(3):156-62. PMID: 26104853.
    View in: PubMed
  19. Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1445-51. PMID: 25858810.
    View in: PubMed
  20. Renteria AS, Sanchorawala V, Niehaus ED, Sun F, Semigran MJ, Seldin DC. Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis. Bone Marrow Transplant. 2015 Jun; 50(6):868-9. PMID: 25751645.
    View in: PubMed
  21. Sanchorawala V. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Hematol Oncol Clin North Am. 2014 Dec; 28(6):1131-44. PMID: 25459183.
    View in: PubMed
  22. Fu J, Seldin DC, Berk JL, Sun F, O'Hara C, Cui H, Sanchorawala V. Lymphadenopathy as a manifestation of amyloidosis: a case series. Amyloid. 2014 Dec; 21(4):256-60. PMID: 25208081.
    View in: PubMed
  23. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014 Oct 16; 124(16):2498-506. PMID: 25202139.
    View in: PubMed
  24. Freeman B, Brauneis D, Seldin DC, Quillen K, Sloan JM, Renteria AS, Shelton AC, Teschner T, Finn KT, Sanchorawala V. Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis. Bone Marrow Transplant. 2014 Oct; 49(10):1345-6. PMID: 24955784.
    View in: PubMed
  25. Lee SY, Sanchorawala V, Seldin DC, Mark Sloan J, Andrea N, Quillen K. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid. 2014 Sep; 21(3):149-53. PMID: 24779777.
    View in: PubMed
  26. Lichtman EI, Seldin DC, Shelton A, Sanchorawala V. Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. Am J Hematol. 2014 Jul; 89(7):706-8. PMID: 24668858.
    View in: PubMed
  27. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014 Feb; 99(2):209-21. PMID: 24497558.
    View in: PubMed
  28. von Keudell G, Sanchorawala V, O'Hara C, C Seldin D, Sloan JM. Simultaneous presentation of kappa-restricted chronic lymphocytic leukemia and lambda light chain AL amyloidosis. Amyloid. 2014 Jun; 21(2):124-7. PMID: 24471777.
    View in: PubMed
  29. Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL, Berk JL, Doros G, Sanchorawala V. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplant. 2014 Mar; 49(3):434-9. PMID: 24317129.
    View in: PubMed
  30. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplant. 2013 Nov; 48(12):1537-42. PMID: 23852321.
    View in: PubMed
  31. Girnius S, Seldin DC, Cibeira MT, Sanchorawala V. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. J Clin Oncol. 2013 Jul 20; 31(21):2749-50. PMID: 23775968.
    View in: PubMed
  32. Sanchorawala V, Shelton AC, Zeldis JB, Seldin DC. Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide. Am J Hematol. 2013 Aug; 88(8):719. PMID: 23650113.
    View in: PubMed
  33. Sarosiek S, Seldin DC, Berk JL, Sanchorawala V. A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature. Amyloid. 2013 Jun; 20(2):127-30. PMID: 23461593.
    View in: PubMed
  34. Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. Transpl Infect Dis. 2013 Apr; 15(2):187-94. PMID: 23279695.
    View in: PubMed
  35. Tsai SB, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, Sloan JM, Doros G, Finn KT, Skinner M, Sanchorawala V. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood. 2012 Nov 22; 120(22):4445-6. PMID: 23175664.
    View in: PubMed
  36. Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013 May; 98(5):789-92. PMID: 23144200.
    View in: PubMed
  37. Cowan AJ, Seldin DC, Skinner M, Quillen K, Doros G, Tan J, O'Hara C, Finn KT, Sanchorawala V. Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1935-8. PMID: 22842332.
    View in: PubMed
  38. Cowan AJ, Skinner M, Seldin DC, Berk JL, Lichtenstein DR, O'Hara CJ, Doros G, Sanchorawala V. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica. 2013 Jan; 98(1):141-6. PMID: 22733017.
    View in: PubMed
  39. Freeman B, Sloan JM, Seldin DC, Cowan AJ, Ruberg FL, Sanchorawala V. Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review. Amyloid. 2012 Sep; 19(3):156-60. PMID: 22680044.
    View in: PubMed
  40. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012 Nov; 26(11):2317-25. PMID: 22475872.
    View in: PubMed
  41. Seldin DC, Sanchorawala V. Amyloidomics comes of age. Blood. 2012 Feb 23; 119(8):1795-6. PMID: 22361969.
    View in: PubMed
  42. Sanchorawala V, Seldin DC. AL amyloidosis: who, what, when, why, and where. Oncology (Williston Park). 2012 Feb; 26(2):164, 166, 169. PMID: 22489350.
    View in: PubMed
  43. Sanchorawala V. Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Am J Blood Res. 2012; 2(1):9-17. PMID: 22432083.
    View in: PubMed
  44. Meier-Ewert HK, Sanchorawala V, Berk JL, Ruberg FL. Cardiac amyloidosis: evolving approach to diagnosis and management. Curr Treat Options Cardiovasc Med. 2011 Dec; 13(6):528-42. PMID: 21989745.
    View in: PubMed
  45. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica. 2011 Dec; 96(12):1890-2. PMID: 21859734.
    View in: PubMed
  46. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011 Oct 20; 118(16):4346-52. PMID: 21828140.
    View in: PubMed
  47. Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, Van De Velde H, Mortimer S, Cakana A, Comenzo RL. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM. 2011 Nov; 104(11):957-70. PMID: 21752867.
    View in: PubMed
  48. Meier-Ewert HK, Sanchorawala V, Berk J, Finn KT, Skinner M, Seldin DC, Ruberg FL. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid. 2011 Jun; 18 Suppl 1:130-1. PMID: 21838460.
    View in: PubMed
  49. Seldin DC, Andrea N, Berenbaum I, Berk JL, Connors L, Dember LM, Doros G, Fennessey S, Finn K, Girnius S, Lerner A, Libbey C, Meier-Ewert HK, O'Connell R, O'Hara C, Quillen K, Ruberg FL, Sam F, Segal A, Shelton A, Skinner M, Sloan JM, Wiesman JF, Sanchorawala V. High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid. 2011 Jun; 18 Suppl 1:127-9. PMID: 21838459.
    View in: PubMed
  50. Seldin DC, Berk JL, Sam F, Sanchorawala V. Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment. Heart Fail Clin. 2011 Jul; 7(3):385-93. PMID: 21749890.
    View in: PubMed
  51. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Jul 28; 118(4):865-73. PMID: 21562045.
    View in: PubMed
  52. Tsai SB, Seldin DC, Wu H, O'Hara C, Ruberg FL, Sanchorawala V. Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid. 2011 Sep; 18(3):160-4. PMID: 21504342.
    View in: PubMed
  53. Charlot M, Seldin DC, O'hara C, Skinner M, Sanchorawala V. Localized amyloidosis of the breast: a case series. Amyloid. 2011 Jun; 18(2):72-5. PMID: 21501022.
    View in: PubMed
  54. Cowan AJ, Skinner M, Berk JL, Sloan JM, O'hara C, Seldin DC, Sanchorawala V. Macroglossia - not always AL amyloidosis. Amyloid. 2011 Jun; 18(2):83-6. PMID: 21401321.
    View in: PubMed
  55. Seldin DC, Berk JL, Sam F, Sanchorawala V. Amyloidotic cardiomyopathy: Multidisciplinary approach to diagnosis and treatment. In: Heart Failure Clinics, Ed by Daniel J. Lenihan and Douglas B. Sawyer. 2011.
  56. Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A, Zeldis JB, Sanchorawala V. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood. 2010 Dec 2; 116(23):5071-2. PMID: 21127185.
    View in: PubMed
  57. Sanchorawala V, Seldin DC, Berk JL, Sloan JM, Doros G, Skinner M. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):469-72. PMID: 21156464.
    View in: PubMed
  58. Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen JC, Semigran MJ. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010 Oct 27; 90(8):905-11. PMID: 20733534.
    View in: PubMed
  59. Quillen K, Seldin DC, Finn KT, Sanchorawala V. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplant. 2011 Jul; 46(7):976-80. PMID: 20956955.
    View in: PubMed
  60. Sanchorawala V, Finn KT, Fennessey S, Shelton A, Doros G, Zeldis JB, Seldin DC. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood. 2010 Sep 16; 116(11):1990-1. PMID: 20847211.
    View in: PubMed
  61. Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, Zeldis JB, Dember LM. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant. 2011 Mar; 26(3):881-6. PMID: 20693160.
    View in: PubMed
  62. Girnius S, Seldin DC, Quillen K, Dember LM, Segal A, Sanchorawala V. Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation. Bone Marrow Transplant. 2011 Jan; 46(1):161-2. PMID: 20383204.
    View in: PubMed
  63. Sanchorawala V, Jacobson DR, Seldin DC, Buxbaum JN. The Amyloidoses. In Williams Textbook of Hematology, Ed by Thomas Kipps and Marshall Lichtmann. 2010.
  64. Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Ann Hematol. 2010 Jun; 89(6):579-84. PMID: 20012043.
    View in: PubMed
  65. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009 Aug 20; 114(8):1489-97. PMID: 19498019.
    View in: PubMed
  66. Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica. 2009 Jul; 94(7):1029-32. PMID: 19454500.
    View in: PubMed
  67. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction. Bone Marrow Transplant. 2010 Jan; 45(1):21-4. PMID: 19421171.
    View in: PubMed
  68. Tam M, Seldin DC, Forbes BM, Connors LH, Skinner M, Oran B, Quillen K, Sanchorawala V. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review. Amyloid. 2009; 16(2):103-7. PMID: 20536404.
    View in: PubMed
  69. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma. 2008 Jun; 49(6):1108-15. PMID: 18452093.
    View in: PubMed
  70. Sanchorawala V. AL (Immunoglobulin Light-Chain) Amyloidosis. In Myeloma Therapy: Pursuing the Plasma Cell, Ed by Sagar Lonial. Springer. New York. 2008.
  71. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid. 2007 Dec; 14(4):261-9. PMID: 17968685.
    View in: PubMed
  72. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007 Nov 15; 110(10):3561-3. PMID: 17673601.
    View in: PubMed
  73. Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant. 2007 Sep; 40(6):557-62. PMID: 17589534.
    View in: PubMed
  74. Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease--diagnosis and treatment. Clin J Am Soc Nephrol. 2007 Jul; 2(4):858-67. PMID: 17699503.
    View in: PubMed
  75. Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O'Hara C, Connors L, Skinner M, Seldin DC. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol. 2007 May; 82(5):363-7. PMID: 17205535.
    View in: PubMed
  76. Seldin DC, Sanchorawala V. Adapting to AL amyloidosis. Haematologica. 2006 Dec; 91(12):1591-5. PMID: 17145594.
    View in: PubMed
  77. Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006 Nov; 1(6):1331-41. PMID: 17699366.
    View in: PubMed
  78. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007 Jan 15; 109(2):492-6. PMID: 16960148.
    View in: PubMed
  79. Sanchorawala V, Blanchard E, Seldin DC, O'Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol. 2006 Sep; 81(9):692-5. PMID: 16795060.
    View in: PubMed
  80. Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood. 2006 Dec 1; 108(12):3945-7. PMID: 16926284.
    View in: PubMed
  81. Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, Skinner M, Seldin DC, Sanchorawala V. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):339-43. PMID: 16862166.
    View in: PubMed
  82. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Skinner M, Seldin DC. A phase II trial of lenalidomide for patients with AL amyloidosis. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7524. PMID: 27955467.
    View in: PubMed
  83. Akar H, Seldin DC, Magnani B, O'Hara C, Berk JL, Schoonmaker C, Cabral H, Dember LM, Sanchorawala V, Connors LH, Falk RH, Skinner M. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid. 2005 Dec; 12(4):210-5. PMID: 16399645.
    View in: PubMed
  84. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 2005 Oct; 36(7):597-600. PMID: 16044137.
    View in: PubMed
  85. Berk JL, Wiesman JF, Skinner M, Sanchorawala V. Diaphragm paralysis in primary systemic amyloidosis. Amyloid. 2005 Sep; 12(3):193-6. PMID: 16194876.
    View in: PubMed
  86. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005 Aug; 79(4):319-28. PMID: 16044444.
    View in: PubMed
  87. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 2005 Mar; 35(6):567-75. PMID: 15665842.
    View in: PubMed
  88. Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn KT, Berk JL, Dember LM, Falk RH, Skinner M. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004 Sep 15; 104(6):1888-93. PMID: 15155460.
    View in: PubMed
  89. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004 Feb; 33(4):381-8. PMID: 14676787.
    View in: PubMed
  90. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004 Jan 20; 140(2):85-93. PMID: 14734330.
    View in: PubMed
  91. Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol. 2003 Oct; 74(2):131-5. PMID: 14508801.
    View in: PubMed
  92. Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, Falk RH. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest. 2003 Sep; 124(3):969-77. PMID: 12970025.
    View in: PubMed
  93. Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int. 2003 May; 63(5):1868-73. PMID: 12675865.
    View in: PubMed
  94. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, O'Hara C, Fennessey S, Finn KT, Wright DG, Skinner M, Sanchorawala V. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003 Mar; 3(4):241-6. PMID: 12672274.
    View in: PubMed
  95. Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int. 2003 Mar; 63(3):1051-7. PMID: 12631087.
    View in: PubMed
  96. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM, Finn KT, Skinner M. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol. 2002 Jun; 117(4):886-9. PMID: 12060126.
    View in: PubMed
  97. Akpek G, Lenz G, Lee SM, Sanchorawala V, Wright DG, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo RL. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplant. 2001 Dec; 28(12):1105-9. PMID: 11803350.
    View in: PubMed
  98. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001 Oct; 28(7):637-42. PMID: 11704785.
    View in: PubMed
  99. Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med. 2001 May 1; 134(9 Pt 1):746-53. PMID: 11329232.
    View in: PubMed
  100. Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001 Mar 15; 97(6):1885-7. PMID: 11238135.
    View in: PubMed
  101. Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S, Berk JL, Dember LM, Falk R, Finn K, Skinner M, Vosburgh E. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol. 1999 Mar; 104(3):553-9. PMID: 10086794.
    View in: PubMed
  102. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998 May 15; 91(10):3662-70. PMID: 9573002.
    View in: PubMed
  103. Fan-Harvard P, Sanchorawala V, Oh J, Moser EM, Smith SP. Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures. Ann Pharmacother. 1994 Jul-Aug; 28(7-8):869-72. PMID: 7949502.
    View in: PubMed
Vaishali's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department